Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home Themes Aging & Longevity

The Truth About Full-Body MRIs: A $2,500 Investment in Your Health?

by Team Lumida
May 17, 2024
in Aging & Longevity, Health and Longevity, Lifestyle
Reading Time: 3 mins read
A A
0
man during magnetic resonance imaging

Photo by Charlss GonzHu on Pexels.com

Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp

Key Takeaways

  1. Full-body MRI scans, costing $2,500, are gaining popularity among celebrities.
  2. These scans promise early disease detection but come with potential downsides.
  3. Investors eyeing the preventive healthcare market should watch for growth in services like Prenuvo.

What Happened?

Prenuvo, a company specializing in full-body MRI scans, is drawing attention with its preventive approach to health. Charging $2,500 for a comprehensive scan, Prenuvo aims to detect early signs of disease without using ionizing radiation or contrast dyes.

Founded in 2018 in Vancouver, Prenuvo expanded to New York City in April 2023, fueled by $70 million in series A funding. High-profile investors like 23andMe cofounder Anne Wojcicki and actress Cindy Crawford back the company. Demand is soaring, with new clinics opening across North America. The scans can detect tumors, aneurysms, and hundreds of other conditions.

Why It Matters?

Why should you care about Prenuvo’s MRI scans? The trend toward preventive healthcare is growing, driven by a desire to catch diseases early and maintain better health. Prenuvo’s success reflects this shift, suggesting significant market potential. Investors should note that this service, though costly, appeals to health-conscious individuals and those with high cancer risk in their families.

The company’s expansion indicates strong demand and potential for further growth. However, some medical experts caution against over-reliance on such scans, highlighting the psychological stress and potential for unnecessary follow-ups.

What’s Next?

What does the future hold for Prenuvo and similar preventive health services? Prenuvo aims to make its scans a routine part of health check-ups, similar to dental visits or physicals. The company plans to work with employers to offer scans as a benefit, potentially increasing accessibility.

For investors, this represents a growing niche in the healthcare market with substantial room for expansion. As the debate over the efficacy and necessity of full-body MRIs continues, Prenuvo’s focus on preventive care could shape future healthcare trends. Watch for further developments and potential collaborations that may influence the company’s market presence and profitability.

Previous Post

Why Investors Are Going Crazy for Copper: The $43 Billion Battle

Next Post

Inside Equinox’s Elite $40,000 Longevity Program: What You Need to Know

Recommended For You

FDA Orders Vision-Loss Warnings on Every GLP-1 Drug After Trials Show NAION Rates of 6.4 vs. 3.8 per 100,000 Patient-Years

by Team Lumida
2 days ago
Bernie Sanders Pushes for Cheaper Wegovy: Can Novo Nordisk Resist?

The FDA will require all GLP-1 drugs, including Wegovy and Zepbound, to warn of a rare optic nerve condition that can cause sudden, permanent vision loss.

Read more

Lilly’s Foundayo Pill Cuts Sleep Apnea Severity by 43.8% in a Late-Stage Trial, Setting Up an FDA Filing by Year-End

by Team Lumida
3 days ago

Eli Lilly’s Foundayo pill cut sleep apnea events by 21.1 an hour vs. 4.8 on placebo, and Lilly plans to seek U.S. approval by year-end.

Read more

‘Buy, Borrow and Die’ Is Now a $5.4 Trillion Lending Market, and Schwab’s 35% Jump Shows It Is Spreading Beyond the Ultrarich

by Team Lumida
2 weeks ago

Lending against stock and bond portfolios has grown to about $5.4 trillion, with 30% in the US, as Schwab’s pledged asset loans jump 35%.

Read more

Schwab Raised the Minimum for These Tax Strategies From $1 Million to $10 Million, Then Said It Will Build Its Own

by Team Lumida
4 weeks ago
Schwab Raised the Minimum for These Tax Strategies From $1 Million to $10 Million, Then Said It Will Build Its Own

Goldman is paying $2.25 billion to acquire exposure to the same trade. Two firms, one IRS warning, opposite responses.

Read more

Ortega’s Family Office Buys a Chicago Tower for $550 Million, Funded by €3.2 Billion of Annual Dividends From One Company

by Team Lumida
4 weeks ago
Ortega’s Family Office Buys a Chicago Tower for $550 Million, Funded by €3.2 Billion of Annual Dividends From One Company

Permanent capital with no fund life and no redemptions is buying trophy offices while leveraged buyers sit out.

Read more

The Last UK Capital Gains Increase Raised Receipts 40%, Mostly Because People Sold Before It Took Effect

by Team Lumida
1 month ago
The Last UK Capital Gains Increase Raised Receipts 40%, Mostly Because People Sold Before It Took Effect

Advisers report clients accelerating deals again to lock in 24% ahead of the October 28 budget. The pattern pulls revenue forward rather than creating it.

Read more

Billionaires Have Raised $318 Million to Defeat a 5% One-Time Wealth Tax That Would Cost One Donor Alone Around $665 Million

by Team Lumida
1 month ago
Billionaires Have Raised $318 Million to Defeat a 5% One-Time Wealth Tax That Would Cost One Donor Alone Around $665 Million

The spending is eight times what supporters have raised, and for any individual contributor it is a fraction of the liability.

Read more

One Covered-Call Fund Reports 94% Return of Capital and a Near-Identical Rival Reports 2.6%, on the Same Index

by Team Lumida
1 month ago
IRS Unveils Crypto Tax Rules: What You Need to Know for 2025

Goldman is buying a firm whose tax position contradicts the one Goldman takes in its own competing funds.

Read more

Treasury Opens a $1,700 Dollar-for-Dollar Tax Credit for School Scholarships, Projected at $26 Billion a Year by 2030

by Team Lumida
1 month ago
Treasury Opens a $1,700 Dollar-for-Dollar Tax Credit for School Scholarships, Projected at $26 Billion a Year by 2030

The credit costs participating taxpayers nothing, and it arrives as half of US school districts already run operating deficits.

Read more

Clearlake Takes Full Control of Chelsea FC in £950M Buyout; Walter, Boehly Exit as Insurance Empires Face Scrutiny

by Team Lumida
2 months ago
Clearlake Takes Full Control of Chelsea FC in £950M Buyout; Walter, Boehly Exit as Insurance Empires Face Scrutiny

Mark Walter and Todd Boehly sell 25% Chelsea stakes for £950M; Clearlake gains full control at £5B valuation; Walter and Boehly liquidating assets as insurers come under pressure.

Read more
Next Post
woman wearing black sports bra

Inside Equinox’s Elite $40,000 Longevity Program: What You Need to Know

Solar Charging Station in the Parking Lot

Xpeng Charges Into Hong Kong with New EV Models

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

PIMCO Stracke: AI Spending Drove Yields, Not Inflation; Hyperscaler Capital Demand Primary Force; Real Rates Rising; Micron Capex Evidence; Break-Even Inflation 2.3% (Stable All Year); Fed Credibility Intact; Deleveraging + Carry Trade Unwind; France 10-Year +100bp Since June; Worst Quarter Since Euro Birth

PIMCO Stracke: AI Spending Drove Yields, Not Inflation; Hyperscaler Capital Demand Primary Force; Real Rates Rising; Micron Capex Evidence; Break-Even Inflation 2.3% (Stable All Year); Fed Credibility Intact; Deleveraging + Carry Trade Unwind; France 10-Year +100bp Since June; Worst Quarter Since Euro Birth

October 2, 2026
Turkey’s Bold Move: 40% Tariff on Chinese Vehicles to Combat Inflation

One Million Car Buyers Have Left the Market — and Automakers Are Fine With It

May 28, 2026

McDonald’s Rises 5% as $3.57 EPS Tops Estimates and U.S. Same-Store Sales Dip Only 0.2%, Beating Fears of a Deeper Slide After Its Value Push

November 4, 2026

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Legacy
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Opinions
    • Investing Philosophy
    • Op-Ed
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Investing Philosophy
  • Latest
  • Legacy
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Op-Ed
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips Amazon Apple Artificial Intelligence Banking Bank of America China Commercial Real Estate CPI data centers Donald Trump EARNINGS ELON MUSK Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Novo Nordisk Nuclear Energy Nvidia oil OpenAI private equity S&P 500 SEC Semiconductor stock market stock surge Tech Stocks tesla Trump Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018